These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 29320974

  • 1. Head to head comparison of adverse effects and efficacy between high dose deflazacort and high dose prednisolone in systemic lupus erythematosus: a prospective cohort study.
    Ganapati A, Ravindran R, David T, Yadav B, Jeyaseelan V, Jeyaseelan L, Danda D.
    Lupus; 2018 May; 27(6):890-898. PubMed ID: 29320974
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Comparison of two glucocorticoid preparations (deflazacort and prednisone) in the treatment of immune-mediated diseases.
    Scudeletti M, Puppo F, Lanza L, Mantovani L, Bosco O, Iudice A, Imbimbo B, Indiveri F.
    Eur J Clin Pharmacol; 1993 May; 45 Suppl 1():S29-34. PubMed ID: 8313931
    [Abstract] [Full Text] [Related]

  • 6. Dose-dependent effects of deflazacort and prednisone on growth and skeletal maturation.
    Aicardi G, Benso L, Vignolo M, Terragna A, Verrina E, Cordone G, Coppo R, Sernia O, Sardella ML, Di Battista E.
    Br J Rheumatol; 1993 May; 32 Suppl 2():39-43. PubMed ID: 8495279
    [Abstract] [Full Text] [Related]

  • 7. In vitro improvement of chlorambucil-induced cytotoxicity by deflazacort and 6-methylprednisolone in B-cell chronic lymphocytic leukaemia.
    Morabito F, Callea I, Irrera G, Cartisano G, Dattola A, Rodinò A, Brugiatelli M.
    Eur J Haematol; 1997 May; 58(5):301-6. PubMed ID: 9222284
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy.
    Griggs RC, Miller JP, Greenberg CR, Fehlings DL, Pestronk A, Mendell JR, Moxley RT, King W, Kissel JT, Cwik V, Vanasse M, Florence JM, Pandya S, Dubow JS, Meyer JM.
    Neurology; 2016 Nov 15; 87(20):2123-2131. PubMed ID: 27566742
    [Abstract] [Full Text] [Related]

  • 10. Glucocorticoid tapering and associated outcome in patients with newly diagnosed systemic lupus erythematosus: the real-world GULP prospective observational study.
    Floris A, Chessa E, Sebastiani GD, Prevete I, Iannone F, Coladonato L, Govoni M, Bortoluzzi A, Mosca M, Tani C, Doria A, Iaccarino L, Franceschini F, Fredi M, Conti F, Spinelli FR, Bellisai F, D'Alessandro R, Zanetti A, Carrara G, Scirè CA, Cauli A, Piga M, study group on Early SLE of the Italian Society of Rheumatology (SIR).
    RMD Open; 2022 Dec 15; 8(2):. PubMed ID: 36581383
    [Abstract] [Full Text] [Related]

  • 11. Deflazacort in comparison to other steroids for nephrotic syndrome.
    Jat KR, Khairwa A.
    Indian J Nephrol; 2012 Jul 15; 22(4):239-45. PubMed ID: 23162265
    [Abstract] [Full Text] [Related]

  • 12. Glucocorticoid-induced osteoporosis in the lumbar spine, forearm, and mandible of nephrotic patients: a double-blind study on the high-dose, long-term effects of prednisone versus deflazacort.
    Olgaard K, Storm T, van Wowern N, Daugaard H, Egfjord M, Lewin E, Brandi L.
    Calcif Tissue Int; 1992 Jun 15; 50(6):490-7. PubMed ID: 1525702
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Compared clinical efficacy and bone metabolic effects of low-dose deflazacort and methyl prednisolone in male inflammatory arthropathies: a 12-month open randomized pilot study.
    Saviola G, Abdi Ali L, Shams Eddin S, Coppini A, Cavalieri F, Campostrini L, Sacco S, Bucci M, Cirino G, Rossini M.
    Rheumatology (Oxford); 2007 Jun 15; 46(6):994-8. PubMed ID: 17384176
    [Abstract] [Full Text] [Related]

  • 15. Preliminary study of a traditional Chinese medicine formula in systemic lupus erythematosus patients to taper steroid dose and prevent disease flare-up.
    Liao YN, Liu CS, Tsai TR, Hung YC, Chang SJ, Lin HL, Chen YC, Lai HM, Yu SF, Chen CJ.
    Kaohsiung J Med Sci; 2011 Jul 15; 27(7):251-7. PubMed ID: 21757141
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Isolation and characterization of a degradation product of deflazacort.
    Paulino AS, Rauber G, Deobald AM, Paulino N, Sawaya AC, Eberlin MN, Cardoso SG.
    Pharmazie; 2012 Jun 15; 67(6):495-9. PubMed ID: 22822536
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.